Amgen Inc. $AMGN Stock Sold by Stillwater Wealth Management Group

Stillwater Wealth Management Group reduced its holdings in Amgen Inc. (NASDAQ:AMGN) by 21.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,725 shares of the medical research company’s stock after selling 1,572 shares during the quarter. Amgen accounts for about 1.3% of Stillwater Wealth Management Group’s investment portfolio, making the stock its 27th largest holding. Stillwater Wealth Management Group’s holdings in Amgen were worth $2,413,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Rational Advisors Inc. grew its position in shares of Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock valued at $72,000 after purchasing an additional 24 shares during the period. Beacon Financial Advisory LLC raised its holdings in Amgen by 2.0% during the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after buying an additional 25 shares during the period. James T. Borello RIA raised its holdings in Amgen by 13.6% during the 3rd quarter. James T. Borello RIA now owns 209 shares of the medical research company’s stock worth $88,000 after buying an additional 25 shares during the period. Sweeney & Michel LLC lifted its stake in Amgen by 0.5% in the third quarter. Sweeney & Michel LLC now owns 5,129 shares of the medical research company’s stock valued at $2,162,000 after buying an additional 25 shares in the last quarter. Finally, Legacy Financial Advisors Inc. lifted its stake in Amgen by 0.8% in the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after buying an additional 26 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Mizuho upped their price target on shares of Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Piper Sandler raised their price objective on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. Scotiabank boosted their price objective on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research report on Monday, September 28th. Argus upped their target price on shares of Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. Finally, Bank of America upped their target price on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Amgen currently has an average rating of “Hold” and an average price target of $388.64.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Positive Phase 3 Tezspire results: Amgen and AstraZeneca reported that Tezspire delivered statistically significant and clinically meaningful improvements in eosinophilic esophagitis. Results included sustained symptom improvement through 52 weeks and a 69% histologic remission rate, strengthening the drug’s potential as a growth driver if approved for this indication. Tezspire Phase 3 results
• Positive Sentiment: Analyst targets moved higher: Piper Sandler set a $457 price target, while Goldman Sachs raised its target to $481. The revisions indicate continued confidence in Amgen’s earnings outlook and pipeline, with the Goldman target implying additional upside from recent trading levels. Piper Sandler price target Goldman Sachs price target
• Positive Sentiment: Upcoming oncology presentation: Amgen will present data and host an investor webcast during the European Society for Medical Oncology Congress on October 24. New oncology data could provide further evidence that its pipeline and portfolio can support future growth. Amgen ESMO 2026 presentation
• Neutral Sentiment: Improving investment narrative: Recent coverage highlights Amgen’s earnings beat, expanding oncology and rare-disease portfolio, and strong cash generation. The company’s 2026 earnings guidance and dividend provide support, but investors still want evidence that newer products can deliver sustained growth. Amgen earnings investment story
• Negative Sentiment: Valuation and growth concerns remain: Commentary comparing Amgen with Bristol Myers Squibb notes that Amgen offers stronger top-line momentum but trades at a substantially higher valuation. With shares near their 52-week high, investors may require continued clinical and earnings execution to justify further gains. Amgen versus Bristol Myers Squibb

Amgen Stock Down 0.6%

NASDAQ AMGN traded down $2.73 during trading on Wednesday, hitting $436.21. The stock had a trading volume of 685,921 shares, compared to its average volume of 2,744,948. The company has a market capitalization of $235.83 billion, a PE ratio of 27.11, a P/E/G ratio of 3.11 and a beta of 0.41. The company’s 50-day moving average price is $416.19 and its two-hundred day moving average price is $376.06. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $447.03.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend was Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by corporate insiders.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.